Selected article for: "acute respiratory syndrome and address strategy"
Author: Stefan, Maxwell A.; Light, Yooli K.; Schwedler, Jennifer L.; McIlroy, Peter R.; Courtney, Colleen M.; Saada, Edwin A.; Thatcher, Christine E.; Phillips, Ashlee M.; Bourguet, Feliza A.; Mageeney, Catherine M.; McCloy, Summer A.; Collette, Nicole M.; Negrete, Oscar A.; Schoeniger, Joseph S.; Weilhammer, Dina R.; Harmon, Brooke
Title: Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies
  • Cord-id: 24grr69x
  • Document date: 2021_8_4
    • ID: 24grr69x
    Snippet: The respiratory virus responsible for coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected nearly every aspect of life worldwide, claiming the lives of over 3.9 million people globally, at the time of this publication. Neutralizing humanized nanobody (V(H)H)-based antibodies (V(H)H-huFc) represent a promising therapeutic intervention strategy to address the current SARS-CoV-2 pandemic and provide a powerful toolkit to address future viru
    Document: The respiratory virus responsible for coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected nearly every aspect of life worldwide, claiming the lives of over 3.9 million people globally, at the time of this publication. Neutralizing humanized nanobody (V(H)H)-based antibodies (V(H)H-huFc) represent a promising therapeutic intervention strategy to address the current SARS-CoV-2 pandemic and provide a powerful toolkit to address future virus outbreaks. Using a synthetic, high-diversity V(H)H bacteriophage library, several potent neutralizing V(H)H-huFc antibodies were identified and evaluated for their capacity to tightly bind to the SARS-CoV-2 receptor-binding domain, to prevent binding of SARS-CoV-2 spike (S) to the cellular receptor angiotensin-converting enzyme 2, and to neutralize viral infection. Preliminary preclinical evaluation of multiple V(H)H-huFc antibody candidates demonstrate that they are prophylactically and therapeutically effective in vivo against wildtype SARS-CoV-2. The identified and characterized V(H)H-huFc antibodies described herein represent viable candidates for further preclinical evaluation and another tool to add to our therapeutic arsenal to address the COVID-19 pandemic.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory syndrome and adjusted diversity: 1
    • acute respiratory syndrome and loop length: 1
    • acute respiratory syndrome and lung blood: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lung blood parenchyma: 1
    • acute respiratory syndrome and lung viral titer: 1, 2
    • acute respiratory syndrome and lung viral titer reduce: 1
    • acute respiratory syndrome coronavirus and additional hour: 1, 2
    • acute respiratory syndrome coronavirus and loop length: 1
    • acute respiratory syndrome coronavirus and lung blood: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome coronavirus and lung blood parenchyma: 1
    • acute respiratory syndrome coronavirus and lung viral titer: 1, 2
    • acute respiratory syndrome coronavirus and lung viral titer reduce: 1